retatrutide type 2 diabetes phase 2 results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished What Is Retatrutide? Side Effects,
Description
Phase 2 data focused on metabolic outcomes, and GLP-1 receptor activity in mood-regulating brain regions remains a theoretical rather than proven concern
The question is what else is going with it
(2005) Exenatide pharmacokinetics/pharmacodynamics/safety (PubMed) Three years of liraglutide vs placebo for type 2 diabetes risk reduction and weight management (The Lancet) Janzen KM, Steuber TD, Nisly SA
"Vegas Golden Knights reveal Chance as team's mascot"
Liraglutide also alleviated SAH-induced early brain injury and inflammation
